Session » Abstracts: Systemic Sclerosis & Related Disorders – Clinical (0496–0501)
- 3:30PM-3:45PM
-
Abstract Number: 0496
Safety and Efficacy of Rituximab for Systemic Sclerosis: A Double-Blind, Parallel-Group Comparison, Investigators Initiated Confirmatory Randomized Clinical Trial (DESIRES Study)
- 3:45PM-4:00PM
-
Abstract Number: 0497
Efficacy in Patient Subgroups in the INCREASE Trial, a Phase III Trial to Evaluate Inhaled Treprostinil in Patients with Pulmonary Hypertension Due to Parenchymal Lung Disease
- 4:00PM-4:15PM
-
Abstract Number: 0498
Background Mycophenolate (MMF) Treatment Is Associated with Improved Outcomes in a Phase 3 Trial of Lenabasum in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
- 4:15PM-4:30PM
-
Abstract Number: 0499
Preliminary Assessment of Internal Reliability and Construct Validity of Long and Short-form Assessment of Systemic Sclerosis-associated RAynaud’s Phenomenon (ASRAP) Questionnaires
- 4:30PM-4:45PM
-
Abstract Number: 0500
Clinical Phenotypes of Patients with Systemic Sclerosis with Distinct Molecular Signatures in the Skin
- 4:45PM-5:00PM
-
Abstract Number: 0501
Immunogenicity of a Single Dose of Covid-19 Vaccination in Patients with Systemic Sclerosis with or Without Immunosupression